JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v10i2.14098ArticleMitophagy Pathways and Therapeutic Applications in Renal Fibrosishttps://artdesignp.com/journal/JCNR/10/2/10.26689/jcnr.v10i2.14098YangXinyue,JiaLonghao,GaoJing,WangLi,LiuJian,TanRuizhi20261022026-03-10Chronic kidney disease (CKD), a global health burden, progresses through renal fibrosis driven by mitochondrial dysfunction in metabolically active renal cells. As the kidney harbors exceptionally high mitochondrial density, defective mitophagy, a quality control mechanism for clearing damaged mitochondria have emerged as a central pathological trigger. Environmental toxins, such as perfluorinated compounds, disrupt lysosomal-mitochondrial crosstalk, exacerbating fibrotic pathways via metabolic reprogramming and sustained activation of pro-fibrotic signaling axes like FGF9/PI3K/Akt. Impaired PINK1/Parkin-mediated mitophagy permits accumulation of fragmented mitochondria, fueling oxidative stress and TGF-β/Smad3-driven epithelial-mesenchymal transition (EMT) and fibroblast activation. Recent therapeutic advances focus on restoring mitophagic flux to counteract fibrosis. Small-molecule activators (UMI-77) enhance mitochondrial clearance, attenuating NF-κB-mediated inflammation and collagen deposition. Nanotechnology-augmented mesenchymal stem cells offer targeted delivery of mitophagy modulators to damaged tubules, synergizing mitochondrial repair with anti-inflammatory effects. While preclinical studies highlight promising agents like SS-31 and MitoQ, challenges persist in achieving tissue-specific mitochondrial targeting and ensuring long-term genomic safety. This review synthesizes molecular insights into mitophagy dysregulation in fibrosis, explores innovative intervention strategies, and underscores the need for multi-omics approaches to optimize mitochondrial therapeutics. Bridging translational gaps through advanced delivery systems and patient-specific mitochondrial profiling may unlock precision therapies for halting CKD progression.

Li J, Lin Q, Shao X, et al., 2023, HIF1α-BNIP3-Mediated Mitophagy Protects Against Renal Fibrosis by Decreasing ROS and Inhibiting Activation of the NLRP3 Inflammasome. Cell Death & Disease, 14(3): 200.

Glassock R, Warnock D, Delanaye P, 2017, The Global Burden of Chronic Kidney Disease: Estimates, Variability and Pitfalls. Nature Reviews Nephrology, 13(2): 104–114.

Stewart S, Kalra P, Blakeman T, et al., 2024, Chronic Kidney Disease: Detect, Diagnose, Disclose—A UK Primary Care Perspective of Barriers and Enablers to Effective Kidney Care. BMC Medicine, 22(1): 331.

Huang R, Fu P, Ma L, 2023, Kidney Fibrosis: From Mechanisms to Therapeutic Medicines. Signal Transduction and Targeted Therapy, 8(1): 129.

Allison S, 2013, Fibrosis: The Source of Myofibroblasts in Kidney Fibrosis. Nature Reviews Nephrology, 9(9): 494.

Hong K, Belperio J, Keane M, et al., 2007, Differentiation of Human Circulating Fibrocytes as Mediated by Transforming Growth Factor-β and Peroxisome Proliferator-Activated Receptor-γ. Journal of Biological Chemistry, 282(31): 22910–22920.

Nikolic-Paterson D, Wang S, Lan H, 2014, Macrophages Promote Renal Fibrosis Through Direct and Indirect Mechanisms. Kidney International Supplements, 4(1): 34–38.

Panizo S, Martínez-Arias L, Alonso-Montes C, et al., 2021, Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. International Journal of Molecular Sciences, 22(1): 408.

Higgins G, Coughlan M, 2014, Mitochondrial Dysfunction and Mitophagy: The Beginning and End to Diabetic Nephropathy? British Journal of Pharmacology, 171(8): 1917–1942.

Bhatia D, Chung K, Nakahira K, et al., 2019, Mitophagy-Dependent Macrophage Reprogramming Protects Against Kidney Fibrosis. JCI Insight, 4(23): e132826.

Eisner V, Picard M, Hajnóczky G, 2018, Mitochondrial Dynamics in Adaptive and Maladaptive Cellular Stress Responses. Nature Cell Biology, 20(7): 755–765.

Sebastián D, Palacín M, Zorzano A, 2017, Mitochondrial Dynamics: Coupling Mitochondrial Fitness with Healthy Aging. Trends in Molecular Medicine, 23(3): 201–215.

Lu Y, Li Z, Zhang S, et al., 2023, Cellular Mitophagy: Mechanism, Roles in Diseases and Small Molecule Pharmacological Regulation. Theranostics, 13(2): 736–766.

Bhargava P, Schnellmann R, 2017, Mitochondrial Energetics in the Kidney. Nature Reviews Nephrology, 13(10): 629–646.

Suliman H, Piantadosi C, 2016, Mitochondrial Quality Control as a Therapeutic Target. Pharmacological Reviews, 68(1): 20–48.

McWilliams T, Prescott A, Allen G, et al., 2016, mito-QC Illuminates Mitophagy and Mitochondrial Architecture In Vivo. Journal of Cell Biology, 214(3): 333–345.

Zhao C, Chen Z, Qi J, et al., 2017, Drp1-Dependent Mitophagy Protects Against Cisplatin-Induced Apoptosis of Renal Tubular Epithelial Cells by Improving Mitochondrial Function. Oncotarget, 8(13): 20988–21000.

Kimura T, Isaka Y, Yoshimori T, 2017, Autophagy and Kidney Inflammation. Autophagy, 13(6): 997–1003.

Castellone M, Laukkanen M, 2017, TGF-β1, WNT, and SHH Signaling in Tumor Progression and in Fibrotic Diseases. Frontiers in Bioscience (Scholar Edition), 9(1): 31–45.

Liu S, Soong Y, Seshan S, et al., 2014, Novel Cardiolipin Therapeutic Protects Endothelial Mitochondria During Renal Ischemia and Mitigates Microvascular Rarefaction, Inflammation, and Fibrosis. American Journal of Physiology—Renal Physiology, 306(9): F970–F980.

Eirin A, Ebrahimi B, Zhang X, et al., 2014, Mitochondrial Protection Restores Renal Function in Swine Atherosclerotic Renovascular Disease. Cardiovascular Research, 103(4): 461–472.

Yin L, Li H, Liu Z, et al., 2021, PARK7 Protects Against Chronic Kidney Injury and Renal Fibrosis by Inducing SOD2 to Reduce Oxidative Stress. Frontiers in Immunology, 12: 690697.

Klahr S, Morrissey J, 1998, Angiotensin II and Gene Expression in the Kidney. American Journal of Kidney Diseases, 31(1): 171–176.

Ishidoya S, Morrissey J, McCracken R, et al., 1995, Angiotensin II Receptor Antagonist Ameliorates Renal Tubulointerstitial Fibrosis Caused by Unilateral Ureteral Obstruction. Kidney International, 47(5): 1285–1294.

Brewster U, Setaro J, Perazella M, 2003, The Renin-Angiotensin-Aldosterone System: Cardiorenal Effects and Implications for Renal and Cardiovascular Disease States. American Journal of the Medical Sciences, 326(1): 15–24.

Wolf G, 2006, Renal Injury Due to Renin-Angiotensin-Aldosterone System Activation of the Transforming Growth Factor-β Pathway. Kidney International, 70(11): 1914–1919.

Nogueira A, Pires M, Oliveira P, 2017, Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. In Vivo, 31(1): 1–22.

La Russa A, Serra R, Faga T, et al., 2024, Kidney Fibrosis and Matrix Metalloproteinases (MMPs). Frontiers in Bioscience (Landmark Edition), 29(5): 192.

Cui N, Hu M, Khalil R, 2017, Biochemical and Biological Attributes of Matrix Metalloproteinases. Progress in Molecular Biology and Translational Science, 147: 1–73.

Fragiadaki M, Mason R, 2011, Epithelial-Mesenchymal Transition in Renal Fibrosis—Evidence for and against. International Journal of Experimental Pathology, 92(3): 143–150.

Garcia-Fernandez N, Jacobs-Cachá C, Mora-Gutiérrez J, et al., 2020, Matrix Metalloproteinases in Diabetic Kidney Disease. Journal of Clinical Medicine, 9(2): 472.

Young D, Das N, Anowai A, et al., 2019, Matrix Metalloproteases as Influencers of the Cells’ Social Media. International Journal of Molecular Sciences, 20(16): 3847.

Ostendorf T, Boor P, van Roeyen C, et al., 2014, Platelet-Derived Growth Factors (PDGFs) in Glomerular and Tubulointerstitial Fibrosis. Kidney International Supplements, 4(1): 65–69.

Boor P, Ostendorf T, Floege J, 2014, PDGF and the Progression of Renal Disease. Nephrology Dialysis Transplantation, 29(Suppl 1): i45–i54.

Yao L, Zhao R, He S, et al., 2022, Effects of Salvianolic Acid A and Salvianolic Acid B in Renal Interstitial Fibrosis via PDGF-C/PDGFR-α Signaling Pathway. Phytomedicine, 106: 154414.

Kok H, Falke L, Goldschmeding R, et al., 2014, Targeting CTGF, EGF and PDGF Pathways to Prevent Progression of Kidney Disease. Nature Reviews Nephrology, 10(12): 700–711.

Kuppe C, Ibrahim M, Kranz J, et al., 2021, Decoding Myofibroblast Origins in Human Kidney Fibrosis. Nature, 589(7841): 281–286.

Livingston M, Shu S, Fan Y, et al., 2023, Tubular Cells Produce FGF2 via Autophagy After Acute Kidney Injury Leading to Fibroblast Activation and Renal Fibrosis. Autophagy, 19(1): 256–277.

Li L, Fu H, Liu Y, 2022, The Fibrogenic Niche in Kidney Fibrosis: Components and Mechanisms. Nature Reviews Nephrology, 18(9): 545–557.

Travers J, Kamal F, Robbins J, et al., 2016, Cardiac Fibrosis: The Fibroblast Awakens. Circulation Research, 118(6): 1021–1040.

Shu D, Lovicu F, 2017, Myofibroblast Transdifferentiation: The Dark Force in Ocular Wound Healing and Fibrosis. Progress in Retinal and Eye Research, 60: 44–65.

Bhatia D, Capili A, Nakahira K, et al., 2022, Conditional Deletion of Myeloid-Specific Mitofusin 2 but Not Mitofusin 1 Promotes Kidney Fibrosis. Kidney International, 101(5): 963–986.

Khalil H, Kanisicak O, Prasad V, et al., 2017, Fibroblast-Specific TGF-β-Smad2/3 Signaling Underlies Cardiac Fibrosis. Journal of Clinical Investigation, 127(10): 3770–3783.

Chung J, Zhang Y, Ji Z, et al., 2023, Immunodynamics of Macrophages in Renal Fibrosis. Integrative Medicine in Nephrology and Andrology, 10(3): e00001.

Manfioletti G, Fedele M, 2022, Epithelial-Mesenchymal Transition (EMT) 2021. International Journal of Molecular Sciences, 23(10): 5848.

López-Novoa J, Nieto M, 2009, Inflammation and EMT: An Alliance Towards Organ Fibrosis and Cancer Progression. EMBO Molecular Medicine, 1(6–7): 303–314.

Li M, Luan F, Zhao Y, et al., 2016, Epithelial-Mesenchymal Transition: An Emerging Target in Tissue Fibrosis. Experimental Biology and Medicine, 241(1): 11–13.

Marconi G, Fonticoli L, Rajan T, et al., 2021, Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in Wound Healing, Tissue Regeneration and Organ Fibrosis. Cells, 10(7): 1587.

Fintha A, Gasparics Á, Rosivall L, et al., 2019, Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition—An Outstanding Challenge. Frontiers in Pharmacology, 10: 388.

Balzer M, Susztak K, 2020, The Interdependence of Renal Epithelial and Endothelial Metabolism and Cell State. Science Signaling, 13(635): eabb8834.

Lovisa S, LeBleu V, Tampe B, et al., 2015, Epithelial-to-Mesenchymal Transition Induces Cell Cycle Arrest and Parenchymal Damage in Renal Fibrosis. Nature Medicine, 21(9): 998–1009.

Grande M, Sánchez-Laorden B, López-Blau C, et al., 2015, Snail1-Induced Partial Epithelial-to-Mesenchymal Transition Drives Renal Fibrosis in Mice and Can Be Targeted to Reverse Established Disease. Nature Medicine, 21(9): 989–997.

Liu Y, 2010, New Insights into Epithelial-Mesenchymal Transition in Kidney Fibrosis. Journal of the American Society of Nephrology, 21(2): 212–222.

Zeisberg M, Kalluri R, 2013, Cellular Mechanisms of Tissue Fibrosis. 1. Common and Organ-Specific Mechanisms Associated with Tissue Fibrosis. American Journal of Physiology—Cell Physiology, 304(3): C216–C225.

Humphreys B, Lin S, Kobayashi A, et al., 2010, Fate Tracing Reveals the Pericyte and Not Epithelial Origin of Myofibroblasts in Kidney Fibrosis. American Journal of Pathology, 176(1): 85–97.

Duffield J, 2014, Cellular and Molecular Mechanisms in Kidney Fibrosis. Journal of Clinical Investigation, 124(6): 2299–2306.

Kramann R, DiRocco D, Humphreys B, 2014, Understanding the Origin, Activation and Regulation of Matrix-Producing Myofibroblasts for Treatment of Fibrotic Disease. Journal of Pathology, 231(3): 273–289.

Mack M, Yanagita M, 2015, Origin of Myofibroblast and Cellular Events Triggering Fibrosis. Kidney International, 87(2): 297–307.

LeBleu V, Taduri G, O’Connell J, et al., 2013, Origin and Function of Myofibroblasts in Kidney Fibrosis. Nature Medicine, 19(8): 1047–1053.

Rockey D, Bell P, Hill J, 2015, Fibrosis—A Common Pathway to Organ Injury and Failure. New England Journal of Medicine, 372(12): 1138–1149.

Meng X, Nikolic-Paterson D, Lan H, 2016, TGF-β: The Master Regulator of Fibrosis. Nature Reviews Nephrology, 12(6): 325–338.

Biernacka A, Dobaczewski M, Frangogiannis N, 2011, TGF-β Signaling in Fibrosis. Growth Factors, 29(5): 196–202.

Wynn T, Ramalingam T, 2012, Mechanisms of Fibrosis: Therapeutic Translation for Fibrotic Disease. Nature Medicine, 18(7): 1028–1040.

Chen Y, Li C, Chen L, 2018, The Crosstalk Between TGF-β Signaling and Inflammatory Pathways in Renal Fibrosis. Journal of Molecular Medicine, 96(5): 503–513.

Lan H, Chung A, Tesch G, et al., 2011, Smad3 Signaling in Renal Fibrosis. Frontiers in Physiology, 2: 82.

Djudjaj S, Boor P, 2019, Cellular and Molecular Mechanisms of Kidney Fibrosis. Molecular Aspects of Medicine, 65: 16–36.

Eddy A, 2014, Overview of the Cellular and Molecular Basis of Kidney Fibrosis. Kidney International Supplements, 4(1): 2–8.

Kaissling B, Lehir M, Kriz W, 2013, Renal Epithelial Injury and Fibrosis. Biochimica et Biophysica Acta—Molecular Basis of Disease, 1832(7): 931–939.

Yang L, Besschetnova T, Brooks C, et al., 2010, Epithelial Cell Cycle Arrest in G2/M Mediates Kidney Fibrosis After Injury. Nature Medicine, 16(5): 535–543.

Nikolic-Paterson D, Wang S, Lan H, 2014, Macrophages Promote Renal Fibrosis Through Direct and Indirect Mechanisms. Kidney International Supplements, 4(1): 34–38.

Guiteras R, Flaquer M, Cruzado J, 2016, Macrophage in Chronic Kidney Disease. Clinical Kidney Journal, 9(6): 765–771.

Tang P, Nikolic-Paterson D, Lan H, 2019, Macrophages: Versatile Players in Renal Inflammation and Fibrosis. Nature Reviews Nephrology, 15(3): 144–158.

Liu B, Cerniglia G, Zhou L, et al., 2018, MCP-1/CCR2 Signaling in Renal Fibrosis and Therapeutic Implications. Frontiers in Physiology, 9: 523.

Chen L, Yang T, Lu D, et al., 2019, Central Role of Dysregulated Renin-Angiotensin System in Kidney Fibrosis. Frontiers in Physiology, 10: 570.

Ruiz-Ortega M, Rayego-Mateos S, Lamas S, et al., 2020, Targeting the Progression of Chronic Kidney Disease. Nature Reviews Nephrology, 16(5): 269–288.

Kanasaki K, Taduri G, Koya D, 2013, Diabetic Nephropathy: The Role of Inflammation in Fibrosis and Endothelial Dysfunction. Frontiers in Endocrinology, 4: 7.

Navarro-González J, Mora-Fernández C, Muros de Fuentes M, et al., 2011, Inflammatory Molecules and Pathways in the Pathogenesis of Diabetic Nephropathy. Nature Reviews Nephrology, 7(6): 327–340.

Sun Y, 2010, Intrarenal Renin-Angiotensin System and Diabetic Nephropathy. Journal of the American Society of Nephrology, 21(10): 1598–1600.

Anders H, Huber T, Isermann B, et al., 2018, CKD in Diabetes: Diabetic Kidney Disease Versus Nondiabetic Kidney Disease. Nature Reviews Nephrology, 14(6): 361–377.

Thomas M, Brownlee M, Susztak K, et al., 2015, Diabetic Kidney Disease. Nature Reviews Disease Primers, 1: 15018.

Forbes J, Cooper M, 2013, Mechanisms of Diabetic Complications. Physiological Reviews, 93(1): 137–188.

Tervaert T, Mooyaart A, Amann K, et al., 2010, Pathologic Classification of Diabetic Nephropathy. Journal of the American Society of Nephrology, 21(4): 556–563.

Alicic R, Rooney M, Tuttle K, 2017, Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clinical Journal of the American Society of Nephrology, 12(12): 2032–2045.

Gilbert R, Cooper M, 1999, The Tubulointerstitium in Progressive Diabetic Kidney Disease: More Than an Afterthought. Kidney International, 56(5): 1627–1637.

Reidy K, Kang H, Hostetter T, et al., 2014, Molecular Mechanisms of Diabetic Kidney Disease. Journal of Clinical Investigation, 124(6): 2333–2340.

Kolset S, Reinholt F, Jenssen T, 2012, Diabetic Nephropathy and Extracellular Matrix. Journal of Histochemistry and Cytochemistry, 60(12): 976–986.

Mason R, Wahab N, 2003, Extracellular Matrix Metabolism in Diabetic Nephropathy. Journal of the American Society of Nephrology, 14(5): 1358–1373.

Kanwar Y, Sun L, Xie P, et al., 2011, A Glimpse of Various Pathogenetic Mechanisms of Diabetic Nephropathy. Annual Review of Pathology: Mechanisms of Disease, 6: 395–423.

Cooper M, 2001, Interaction of Metabolic and Haemodynamic Factors in Mediating Experimental Diabetic Nephropathy. Diabetologia, 44(11): 1957–1972.

Ziyadeh F, 2004, Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator. Journal of the American Society of Nephrology, 15(Suppl 1): S55–S57.

Brosius F, Tuttle K, Kretzler M, 2016, JAK Inhibition in the Treatment of Diabetic Kidney Disease. Diabetologia, 59(8): 1624–1627.

Wada J, Makino H, 2013, Inflammation and the Pathogenesis of Diabetic Nephropathy. Clinical Science, 124(3): 139–152.

Lim A, 2014, Diabetic Nephropathy—Complications and Treatment. International Journal of Nephrology and Renovascular Disease, 7: 361–381.

Pichler R, Afkarian M, Dieter B, et al., 2017, Immunity and Inflammation in Diabetic Kidney Disease: Translating Mechanisms to Biomarkers and Treatment Targets. American Journal of Physiology—Renal Physiology, 312(4): F716–F731.

Navarro J, Mora C, Muros M, et al., 2005, Effects of Pentoxifylline Administration on Urinary N-Acetyl-β-D-Glucosaminidase Excretion in Type 2 Diabetic Patients: A Short-Term Prospective Study. American Journal of Kidney Diseases, 45(3): 490–496.

Fioretto P, Mauer M, 2007, Histopathology of Diabetic Nephropathy. Seminar in Nephrology, 27(2): 195–207.

Qi W, Chen X, Poronnik P, et al., 2006, Transforming Growth Factor-β1 Induces Epithelial-to-Mesenchymal Transition in Human Proximal Tubular Epithelial Cells Through the ERK1/2 Signaling Pathway. Nephrology Dialysis Transplantation, 21(4): 1002–1010.

Hills C, Squires P, 2011, The Role of TGF-β and Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy. Cytokine and Growth Factor Reviews, 22(3): 131–139.

Loeffler I, Wolf G, 2015, Transforming Growth Factor-β & the Progression of Renal Disease. Nephrology Dialysis Transplantation, 30(Suppl 1): i37–i45.

Kato M, Natarajan R, 2014, Diabetic Nephropathy—Emerging Epigenetic Mechanisms. Nature Reviews Nephrology, 10(9): 517–530.

Ruster C, Wolf G, 2006, Angiotensin II as a Morphogenic Cytokine Stimulating Renal Fibrogenesis. Journal of the American Society of Nephrology, 17(7): 1699–1710.

Mezzano S, Ruiz-Ortega M, Egido J, 2001, Angiotensin II and Renal Fibrosis. Hypertension, 38(3 Pt 2): 635–638.

Ruiz-Ortega M, Lorenzo O, Suzuki Y, et al., 2001, Proinflammatory Actions of Angiotensins. Current Opinion in Nephrology and Hypertension, 10(3): 321–329.

Benigni A, Cassis P, Remuzzi G, 2010, Angiotensin II Revisited: New Roles in Inflammation, Immunology and Aging. EMBO Molecular Medicine, 2(7): 247–257.

Wolf G, 2008, Novel Aspects of the Renin-Angiotensin-Aldosterone System. Frontiers in Bioscience, 13: 4993–5005.

Bataller R, Brenner D, 2005, Liver Fibrosis. Journal of Clinical Investigation, 115(2): 209–218.

Leask A, Abraham D, 2004, TGF-β Signaling and the Fibrotic Response. FASEB Journal, 18(7): 816–827.

Border W, Noble N, 1994, Transforming Growth Factor β in Tissue Fibrosis. New England Journal of Medicine, 331(19): 1286–1292.

Eddy A, Neilson E, 2006, Chronic Kidney Disease Progression. Journal of the American Society of Nephrology, 17(11): 2964–2966.

Zeisberg E, Potenta S, Sugimoto H, et al., 2008, Fibroblasts in Kidney Fibrosis Emerge Via Endothelial-to-Mesenchymal Transition. Journal of the American Society of Nephrology, 19(12): 2282–2287.

Li J, Qu X, Ricardo S, et al., 2009, Resveratrol Inhibits Renal Fibrosis in the Obstructed Kidney: Potential Role in Deacetylation of Smad3. American Journal of Pathology, 177(3): 1065–1071.

Pang M, Kothapally J, Mao H, et al., 2009, Inhibition of Histone Deacetylase Activity Attenuates Renal Fibrosis in the Obstructed Kidney. American Journal of Physiology—Renal Physiology, 297(4): F996–F1005.

Yoshikawa M, Hishikawa K, Marumo T, et al., 2007, Inhibition of Histone Deacetylase Activity Suppresses Epithelial-to-Mesenchymal Transition Induced by TGF-β1 in Human Renal Epithelial Cells. Journal of the American Society of Nephrology, 18(1): 58–65.

Klinkhammer B, Goldschmeding R, Floege J, et al., 2017, Treatment of Renal Fibrosis—Turning Challenges into Opportunities. Advances in Chronic Kidney Disease, 24(2): 117–129.

Tampe B, Zeisberg M, 2014, Potential Approaches to Reverse or Repair Renal Fibrosis. Nature Reviews Nephrology, 10(4): 226–237.

Liu Y, 2011, Cellular and Molecular Mechanisms of Renal Fibrosis. Nature Reviews Nephrology, 7(12): 684–696.

Duffield J, Lupher M, Thannickal V, et al., 2013, Host Responses in Tissue Repair and Fibrosis. Annual Review of Pathology: Mechanisms of Disease, 8: 241–276.

Meng X, Tang P, Li J, et al., 2015, Macrophage Phenotype in Kidney Injury and Repair. Kidney International, 87(4): 671–679.

Cao Q, Harris D, Wang Y, 2015, Macrophages in Kidney Injury, Inflammation, and Fibrosis. Physiology, 30(3): 183–194.

Lin S, Kisseleva T, Brenner D, et al., 2008, Pericytes and Perivascular Fibroblasts are the Primary Source of Collagen-Producing Cells in Obstructive Fibrosis of the Kidney. American Journal of Pathology, 173(6): 1617–1627.

Schrimpf C, Duffield J, 2011, Mechanisms of Fibrosis: The Role of the Pericyte. Current Opinion in Nephrology and Hypertension, 20(3): 297–305.

Boor P, Floege J, 2011, Renal Allograft Fibrosis: Biology and Therapeutic Targets. American Journal of Transplantation, 11(5): 897–908.

Hertig A, Verine J, Mougenot B, et al., 2008, Risk Factors for Early Epithelial-to-Mesenchymal Transition in Renal Grafts. American Journal of Transplantation, 8(6): 1272–1279.

Carew R, Wang B, Kantharidis P, 2012, The Role of EMT in Renal Fibrosis. Cell and Tissue Research, 347(1): 103–116.

Zhou D, Fu H, Liu Y, 2018, Renal Fibrosis: Mechanisms and Perspectives of Therapeutic Strategies. Frontiers in Physiology, 9: 1055.

Djudjaj S, Boor P, 2021, Cellular and Molecular Mechanisms of Kidney Fibrosis. Molecular Aspects of Medicine, 65: 100–110.

Lovisa S, Kalluri R, 2018, Fatty Acid Oxidation Regulates the Activation of Fibroblasts in Kidney Fibrosis. Nature Reviews Nephrology, 14(6): 361–362.

Kang H, Ahn S, Choi P, et al., 2015, Defective Fatty Acid Oxidation in Renal Tubular Epithelial Cells Has a Key Role in Kidney Fibrosis Development. Nature Medicine, 21(1): 37–46.

Kato H, Gruenwald A, Suh J, et al., 2020, Wnt/β-Catenin Pathway in Renal Fibrosis: Therapeutic Opportunities. Kidney International, 97(2): 241–254.

Tan R, Zhou D, Zhou L, et al., 2014, Wnt/β-Catenin Signaling and Kidney Fibrosis. Kidney International Supplements, 4(1): 84–90.

He W, Dai C, Li Y, et al., 2009, Wnt/β-Catenin Signaling Promotes Renal Interstitial Fibrosis. Journal of the American Society of Nephrology, 20(4): 765–776.

Zhou D, Tan R, Fu H, et al., 2012, Wnt/β-Catenin Signaling in Kidney Injury and Repair. Journal of the American Society of Nephrology, 23(7): 1110–1117.

Yang J, Liu Y, 2001, Blockage of Tubular Epithelial-to-Myofibroblast Transition by Hepatocyte Growth Factor Prevents Renal Interstitial Fibrosis. Journal of the American Society of Nephrology, 13(1): 96–107.

Mizuno S, Matsumoto K, Nakamura T, 2001, Hepatocyte Growth Factor Suppresses Interstitial Fibrosis in a Mouse Model of Obstructive Nephropathy. Kidney International, 59(4): 1304–1314.

Liu Y, Rajur K, Tolbert E, et al., 1999, Endogenous Hepatocyte Growth Factor Ameliorates Chronic Renal Injury by Inhibiting Renal Fibrosis. American Journal of Physiology—Renal Physiology, 277(5): F791–F799.

Eddy A, 2000, Molecular Insights into Renal Interstitial Fibrosis. Journal of the American Society of Nephrology, 11(2): 249–256.

Boor P, Sebekova K, Ostendorf T, et al., 2007, Treatment Targets in Renal Fibrosis. Nephrology Dialysis Transplantation, 22(12): 3391–3407.

Kanasaki K, Kitada M, Koya D, 2013, Pathophysiology of the Aging Kidney and Therapeutic Interventions. Hypertension Research, 36(10): 873–879.

Humphreys B, 2018, Mechanisms of Renal Fibrosis. Annual Review of Physiology, 80: 309–326.

Mallat A, Lotersztajn S, 2013, Cellular Mechanisms of Tissue Fibrosis. 5. Novel Insights into Liver Fibrosis. American Journal of Physiology—Cell Physiology, 305(8): C789–C799.

Wynn T, Vannella K, 2016, Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity, 44(3): 450–462.

Rockey D, Weymouth N, Shi Z, 2015, Smooth Muscle α-Actin (Acta2) and Myofibroblast Function During Hepatic Wound Healing. PLoS One, 10(3): e0120495.

Darby I, Laverdet B, Bonté F, et al., 2014, Fibroblasts and Myofibroblasts in Wound Healing. Clinical, Cosmetic and Investigational Dermatology, 7: 301–311.

Henderson N, Rieder F, Wynn T, 2020, Fibrosis: From Mechanisms to Medicines. Nature, 587(7835): 555–566.

Kramann R, Humphreys B, 2014, Kidney Pericytes: Roles in Regeneration and Fibrosis. Seminars in Nephrology, 34(4): 374–383.

LeBleu V, Kalluri R, 2018, A Peek into Cancer-Associated Fibroblasts: Origins, Functions and Translational Impact. Disease Models and Mechanisms, 11(4): dmm029538.

Zeisberg M, Neilson E, 2010, Mechanisms of Tubulointerstitial Fibrosis. Journal of the American Society of Nephrology, 21(11): 1819–1834.

Böttinger E, Bitzer M, 2002, TGF-β Signaling in Renal Disease. Journal of the American Society of Nephrology, 13(10): 2600–2610.

Lan H, 2011, Diverse Roles of TGF-β/Smads in Renal Fibrosis and Inflammation. International Journal of Biological Sciences, 7(7): 1056–1067.

Chen H, Li Y, Liu Y, 2012, Roles of Pericytes in Kidney Injury and Fibrosis. Histology and Histopathology, 27(6): 745–753.

Grande M, López-Novoa J, 2009, Fibroblast Activation and Myofibroblast Generation in Obstructive Nephropathy. Nature Reviews Nephrology, 5(6): 319–328.

Zeisberg E, Kalluri R, 2010, Origins of Cardiac Fibroblasts. Circulation Research, 107(11): 1304–1312.

Duffield J, 2010, Macrophages and Immunologic Inflammation of the Kidney. Seminars in Nephrology, 30(3): 234–254.

Susztak K, 2018, Understanding the Epigenetic Syntax for the Genetic Alphabet in the Kidney. Journal of the American Society of Nephrology, 29(1): 14–16.

Fu H, Zhou D, Liu Y, 2018, Wnt Signaling in Kidney Diseases: Lessons Learned and Future Directions. Kidney International, 94(1): 58–67.

Zhou L, Li Y, Zhou D, et al., 2015, Loss of Klotho Contributes to Kidney Injury by Derepression of Wnt/β-Catenin Signaling. Journal of the American Society of Nephrology, 24(5): 771–785.

Liu Y, 2006, Renal Fibrosis: New Insights into the Pathogenesis and Therapeutics. Kidney International, 69(2): 213–217.